Supported by an educational grant from Neurocrine Biosciences, Inc.

Homepage

Featured

Education
CME: Conference Rewind From NP Institute
See More
Videos
Anticholinergics and VMAT-2 Inhibitors: Different MOAs, Different Results
Videos
Unpacking the Patient Experience of Living With Tardive Dyskinesia

Faculty

Craig Chepke, MD, DFAPA
Medical Director,
Excel Psychiatric Associates
Rakesh Jain, MD, MPH
Clinical Professor,
Texas Tech - Permian Basin
Desiree Matthews, PMHNP-BC
CEO,
Different MHP, PC
Jonathan Meyer, MD
Voluntary Clinical Professor of Psychiatry,
University of California,
San Diego School of Medicine

Education

View all
Tardive Dyskinesia (TD) A Quick Guide for Caregivers
CME: Conference Rewind From NP Institute
Moving Mountains with Molecules in Tardive Dyskinesia: Optimizing Strategies for Challenging Cases

Videos

View all
Telehealth AIMS Demo
Anticholinergics and VMAT-2 Inhibitors: Different MOAs, Different Results
AIMS Severity Assessment Video Library

Podcasts

View all
TD in Community Psychiatry: A Hidden Epidemic?
Monitoring TD in Long-Term Care or Geriatric Populations
Shared Decision-Making in TD

News

View all
Drug-Drug Considerations in TD Treatment
Valbenazine Demonstrates Higher Persistence vs Deutetrabenazine in TD Patients
Valbenazine Effective for Long-Term Treatment of TD in Older Adults, Analysis Finds

Posters

View all
Patient Perspective on Barriers to Diagnosis and Treatment of Tardive Dyskinesia: Results From a Cross-Sectional Survey
Impact of Tardive Dyskinesia on Clinical Aspects and Quality of Life Based on Individuals’ Underlying Psychiatric Conditions: Interim Analysis of Baseline Data From the IMPACT-TD Registry
Once-Daily Valbenazine for Tardive Dyskinesia or Huntington’s Disease Chorea in Patients with Dysphagia or Swallowing Difficulties